All News
➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021 POS0236
Comparison of work productivity b/w CBP w & w/o AxSpA - 2 years from SPACE cohort
⭐️AxSpA showed significant ⬇️ in work productivity loss (WPL) compared to CBP wo AxSpA
Can use to counsel AxSpA patients that we have effective Rx for return to work
@RheumNow
Eric Dein ejdein1 ( View Tweet)
#EULAR2021 POS0237: Gut dysbiosis linked to worse disease status in axSpA.
⭐️Dysbiosis in 33% of AxSpA vs 17% of controls wo rheumatic disease
⭐️Gut dysbiosis associated with worsening disease activity
@RheumNow https://t.co/rRl4Zbs7xc
Eric Dein ejdein1 ( View Tweet)
6. Rheum disease activity was stable with COVID vaccination.
(RA, PsA, axSpA, SLE - total n = 597)
7/
LB0003 #EULAR2021 @RheumNow https://t.co/xxkrunjPa0
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Attention bosses!
AxSpA patients who were older and worse disease activity associated with more sick leave
⭐️male gender and higher education associated with less sick leave
Abs#POS0238
#EULAR2021 @RheumNow https://t.co/aSs0BCHjau
Robert B Chao, MD doctorRBC ( View Tweet)
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.
https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
Links:
Dr. John Cush RheumNow ( View Tweet)
Gut dysbiosis linked to worse disease status in AxSpA
⭐️higher dysbiosis associated w/ worse EvalGlobal, ASDAS-CRP, BASDAI, BASFI, VAS pain
⭐️comparing dysbiosis vs. non-dysbiosis group - significant difference in BASDAI, BASFI, EvalGlobal
Abs#POS0237
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2021 POS0227 recs all patients try subQ MTX before bDMARD. Mirza et al: ⬆️ efficacy & ⬇️side effects with subQ.
May not be for all pts, but subQ ⬆️ efficacy than high-dose PO MTX. ⬇️ GI side effects, but ⬆️ ulcers/hair loss (use folate/leucovorin for this)
@RheumNow
Eric Dein ejdein1 ( View Tweet)
Yesterday at #EULAR2021: Spacing trial: success in taper anti-TNF for stable SpA. POS0229 C-OPTIMSE study: Certolizumab w/d for SpA remission (continue full dose vs. 1/2 dose vs. placebo). Placebo group had ⬆️ activity scores, 77% flared. Ok to taper, but won't stop Rx @Rheumnow
Eric Dein ejdein1 ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
SPIRIT-P1&P2 studies showed IXE effective in treating axPsA. When do you consider IL17i in your treatment algorithm in axPsA (as the predominant domain?) Poster #POS1045 #EULAR2021 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
PREVENT: SEC 150 mg showed durable improvement in nr-axSpA through 2 yrs, 438 pts. No new or unexpected safety signals. Poster #POS0900 #EULAR2021 @RheumNow https://t.co/NU1EO9zktn https://t.co/LP3hkZodhi
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2021 and EULAR IQ
Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, & Janssen. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Who responds better to bDMARDs in RA, PsA & SpA? Men, women or equal? POS0208 #EULAR2021 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 312 SpA treated with rap TNFi. Men respond better to TNFi in all groups POS0208 #EULAR2021 @RheumNow @eular_org https://t.co/7FoI3p0qwe
Janet Pope Janetbirdope ( View Tweet)
What can define +MRI for active spine lesions in axSpA?
*⃣ BME in >/=4 vertebral corners (VCs)
*⃣BME in >/= 3 VCs if w/ at least 1 non-corner inflamm lesion
*⃣BME in >/=1 VC if w/ at least 2 VC fat lesions
Such cut-offs achieve >/= 95% specificity
OP0252. #EULAR2021 @Rheumnow https://t.co/5CTan2BgLK
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Phenotypes in axPsA per Dr. Gladman:
⭐️15% develop axial dz at 10y: # of radiographic damaged joints, periostitis, & ⬆️ESR predictive. HLA-B27 no longer predictive
⭐️Buttock pain & IBD more common in axial dz
⭐️M had more axial dz + radiographic damage
#EULAR2021. @Rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr Deodhar on upadacitinib in axial PsA. Appears to be effective in combined analysis of SELECT-PsA 1 and 2. @RheumNow #EULAR2021 Abstr#0233 https://t.co/fBMWVb3oBd
Richard Conway RichardPAConway ( View Tweet)